Effects of oral small spherical activated charcoal (Kremezin) on inflammatory cytokines and coronary plaque component assessed by integrated backscatter intravascular ultrasound

Effects of oral small spherical activated charcoal (Kremezin) on inflammatory cytokines and coronary plaque component assessed by integrated backscatter intravascular ultrasound - Antiarteriosclerotic effect of oral small spherical activated charcoal (Kremezin)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007897

Enrollment

Registered

2012-06-01

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic renal failure patients( eGFRis less than 45 ml/min/1.73m2)

Interventions

1)Tissue characteristics of coronary plaques and levels of inflammatory cytokines were examined 2) Kremezin was added 3)Tissue characteristics of the same coronary plaques and levels of inflammator

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with stable angina planned to be treated with stent 2)Chronic renal failure patients (eGFR<45ml/min/1.73m2) 3)Patients who had been treated with statin(LDL-cho< 100mg/dl) 4)written informed consent before the

Exclusion criteria

Exclusion criteria: 1)Dialysis patients 2)Patients with cancer 3)Patients with a history of coronary artery bypass surgery

Design outcomes

Primary

Measure	Time frame
tissue characterization of coronary plaque levels of inflammatory cytokine	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026